These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 35091679

  • 1. TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer.
    Ma Y, Zhang H, Chen C, Liu L, Ding T, Wang Y, Ma D, Ling X, Chen X, Li J, Guansheng, Zhong, Ru G, Zhang L, Tang J.
    Oncogene; 2022 Mar; 41(11):1589-1599. PubMed ID: 35091679
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim H, Yin T, Fan S, Shen Q.
    Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Obesity-associated metabolic inflammation promotes triple-negative breast cancer progression through the interleukin-6/STAT3/pentraxin 3/matrix metalloproteinase 7 axis.
    Xie H, Ruan G, Wei L, Zhang H, Shi J, Lin S, Liu C, Liu X, Zheng X, Chen Y, Deng L, Shi H.
    Int Immunopharmacol; 2024 Jul 30; 136():112332. PubMed ID: 38805776
    [Abstract] [Full Text] [Related]

  • 13. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M, Li A, Zhou S, Lv H, Yang W.
    J Hematol Oncol; 2019 Feb 08; 12(1):14. PubMed ID: 30736840
    [Abstract] [Full Text] [Related]

  • 14. Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
    Cai Y, Gu WT, Cheng K, Jia PF, Li F, Wang M, Zhang WF, Qiu JT, Wu ZB, Zhao WG.
    Biochem Biophys Res Commun; 2021 Apr 23; 550():134-141. PubMed ID: 33691199
    [Abstract] [Full Text] [Related]

  • 15. TRIM32 promotes cell proliferation and invasion by activating β-catenin signalling in gastric cancer.
    Wang C, Xu J, Fu H, Zhang Y, Zhang X, Yang D, Zhu Z, Wei Z, Hu Z, Yan R, Cai Q.
    J Cell Mol Med; 2018 Oct 23; 22(10):5020-5028. PubMed ID: 30079558
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. STAT3 Targets ERR-α to Promote Epithelial-Mesenchymal Transition, Migration, and Invasion in Triple-Negative Breast Cancer Cells.
    Ma JH, Qi J, Lin SQ, Zhang CY, Liu FY, Xie WD, Li X.
    Mol Cancer Res; 2019 Nov 23; 17(11):2184-2195. PubMed ID: 31427441
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Liu H, Yan R, Xiao Z, Huang X, Yao J, Liu J, An G, Ge Y.
    Breast Cancer Res; 2023 Apr 17; 25(1):43. PubMed ID: 37069669
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of POU3F2 promotes radioresistance in triple-negative breast cancer via Akt pathway activation.
    Zhang H, Zheng J, Fu Y, Ling J, Liu Z, Lin X, Dong X, Sun Y, Tan T, Guo Z, Xie G.
    Breast Cancer Res Treat; 2023 Apr 17; 198(3):437-446. PubMed ID: 36797433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.